【火热】青峰医药入局8亿潜力品种

米内网2025-07-10

精彩内容近日，青峰医药的富马酸伏诺拉生片以仿制4类报产获受理。这是一款钾离子竞争性酸阻滞剂，原研产品2024年在中国三大终端六大市场（统计范围详见本文末）的销售额超过8亿元。今年以来，青峰医药有7个仿制药、1款1类新药首次报产/报临床。富马酸伏诺拉生片是由武田药品开发的一款钾离子竞争性酸阻滞剂(P-CAB)，用于治疗反流性食管炎，也可与适当的抗生素联用以根除幽门螺杆菌。米内网数据显示，富马酸伏诺拉...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550984612?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-10 16:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550984612","market":"sh","top_or_hot":-1,"title":"【火热】青峰医药入局8亿潜力品种","media":"米内网","content":"<div>\n<p>精彩内容近日，青峰医药的富马酸伏诺拉生片以仿制4类报产获受理。这是一款钾离子竞争性酸阻滞剂，原研产品2024年在中国三大终端六大市场（统计范围详见本文末）的销售额超过8亿元。今年以来，青峰医药有7个仿制药、1款1类新药首次报产/报临床。富马酸伏诺拉生片是由武田药品开发的一款钾离子竞争性酸阻滞剂(P-CAB)，用于治疗反流性食管炎，也可与适当的抗生素联用以根除幽门螺杆菌。米内网数据显示，富马酸伏诺拉...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164648a4422a20&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【火热】青峰医药入局8亿潜力品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【火热】青峰医药入局8亿潜力品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-10 16:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164648a4422a20&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容近日，青峰医药的富马酸伏诺拉生片以仿制4类报产获受理。这是一款钾离子竞争性酸阻滞剂，原研产品2024年在中国三大终端六大市场（统计范围详见本文末）的销售额超过8亿元。今年以来，青峰医药有7个仿制药、1款1类新药首次报产/报临床。富马酸伏诺拉生片是由武田药品开发的一款钾离子竞争性酸阻滞剂(P-CAB)，用于治疗反流性食管炎，也可与适当的抗生素联用以根除幽门螺杆菌。米内网数据显示，富马酸伏诺拉...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164648a4422a20&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0096","symbol_name":"民营医院","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164648a4422a20&s=b","article_id":"2550984612","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164648a4422a20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550984612","pubTimestamp":1752136284,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容近日，青峰医药的富马酸伏诺拉生片以仿制4类报产获受理。今年以来，青峰医药有7个仿制药、1款1类新药首次报产/报临床。米内网数据显示，富马酸伏诺拉生片已被纳入国家医保乙类目录，原研产品近年来在中国三大终端六大市场的销售额均以两位数的增速持续增长，2024年突破8亿元，2025年第一季度以35%的增速继续增长。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","600079":"ST人福","BK0096":"民营医院","01093":"石药集团","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","BK0188":"融资融券","BK0070":"员工持股","BK0012":"证金概念"},"translate_title":"[Hot] Qingfeng Pharmaceutical enters 800 million potential varieties","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600079":0.9,"01093":0.9},"content_text":"精彩内容近日，青峰医药的富马酸伏诺拉生片以仿制4类报产获受理。这是一款钾离子竞争性酸阻滞剂，原研产品2024年在中国三大终端六大市场（统计范围详见本文末）的销售额超过8亿元。今年以来，青峰医药有7个仿制药、1款1类新药首次报产/报临床。富马酸伏诺拉生片是由武田药品开发的一款钾离子竞争性酸阻滞剂(P-CAB)，用于治疗反流性食管炎，也可与适当的抗生素联用以根除幽门螺杆菌。米内网数据显示，富马酸伏诺拉生片已被纳入国家医保乙类目录，原研产品近年来在中国三大终端六大市场的销售额均以两位数的增速持续增长，2024年突破8亿元，2025年第一季度以35%的增速继续增长。近年来中国三大终端六大市场富马酸伏诺拉生片销售情况（单位：万元）来源：米内网格局数据库在近日流出的第十一批国采拟采购药品清单征求意见稿中，富马酸伏诺拉生片赫然在列。该药已有21家药企视同过评，包括石药集团、正大制药、石家庄四药、康弘药业、齐鲁制药、人福医药、科伦药业、扬子江药业、鲁南制药等。此外，70余家药企的产品以新分类报产在审，竞争激烈。米内网数据显示，今年以来，青峰医药有7个品种以新注册分类报产，包括3款消化系统及代谢药、2款抗肿瘤和免疫调节剂及2款神经系统药物，其中阿贝西利片、布立西坦注射液、利那洛肽胶囊、布立西坦口服溶液均暂无首仿（含剂型首仿）获批。今年以来青峰医药报产的仿制药来源：米内网中国申报进度（MED）数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550984612","isCrawlerRequest":true}